Jim Lin

US Patent:

7285630, Oct 23, 2007

Filed:

Jul 22, 2002

Appl. No.:

10/201501

Inventors:

Kiron M. Das - Basking Ridge NJ, US
Jim Jung-Chin Lin - Iowa City IA, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ
University of Iowa Research Foundation - Iowa City IA

International Classification:

C07K 14/00

US Classification:

530350, 530326, 4241851, 435 71

Abstract:

A novel isoform of tropomyosin is disclosed. The isoform is closely related to epithelial human tropomyosin (hTM) and more particularly to hTM5 except the last coding exon. The novel isoform, is called TC22. Northern blot analysis with TC22-specific probe revealed that normal culture cell lines and normal epithelial tissues expressed very little, if at all, TC22 message, whereas their transformed counterparts and tumor tissues including dysfunction of the alimentary canal, significantly increased the expression of TC22. Assays directed at determining the level of TC22 are useful in diagnostics and therapeutics of dysfunction of the alimentary canal. Specific antibodies and mimics for TC22 are also disclosed for use in diagnostics and therapeutics of dysfunction of the alimentary canal.

US Patent:

RE43472, Jun 12, 2012

Filed:

Oct 23, 2009

Appl. No.:

12/604840

Inventors:

Kiron M. Das - Basking Ridge NJ, US
Jim Jung-Ching Lin - Iowa City IA, US

Assignee:

University of Medicine and Dentistry of New Jersey - Somerset NJ
University of Iowa Research Foundation - Iowa City IA

International Classification:

C07K 14/00

US Classification:

530350, 530326, 5303871, 5303879, 530806, 4241301, 4241391, 4241781, 4241851, 4241931, 435 71

Abstract:

A novel isoform of tropomyosin is disclosed. The isoform is closely related to epithelial human tropomyosin (hTM) and more particularly to hTM5 except the last coding exon. The novel isoform, is called TC22. Northern blot analysis with TC22-specific probe revealed that normal culture cell lines and normal epithelial tissues expressed very little, if at all, TC22 message, whereas their transformed counterparts and tumor tissues including dysfunction of the alimentary canal, significantly increased the expression of TC22. Assays directed at determining the level of TC22 are useful in diagnostics and therapeutics of dysfunction of the alimentary canal. Specific antibodies and mimics for TC22 are also disclosed for use in diagnostics and therapeutics of dysfunction of the alimentary canal.

US Patent:

20110059924, Mar 10, 2011

Filed:

May 17, 2006

Appl. No.:

11/914849

Inventors:

Kiron M. Das - Basking Ridge NJ, US
Jim Chung-Chin Lin - Iowa City IA, US

Assignee:

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - New Brunswick NJ

International Classification:

A61K 31/655
A61K 31/196
C09B 29/00
C07C 229/64
A61P 35/00
C12Q 1/68
G01N 33/566

US Classification:

514150, 514567, 534664, 562444, 435 6, 435 721

Abstract:

A method for preventing or treating colorectal cancer in a patient possessing human tropomyocin isoform TC22 is presented. Also presented is a method for evaluating TC22 expression reduction activity of a compound.